MAVERICK CAPITAL LTD - 31 Dec 2025 SCHEDULE 13G/A Report for Rocket Pharmaceuticals, Inc. Common stock, $0.01 par value per share (RCKT)

Filing Manager
MAVERICK CAPITAL LTD
Reporting Manager
Maverick Capital, Ltd.
Security
Rocket Pharmaceuticals, Inc. Common stock, $0.01 par value per share
Symbol
RCKT
Shares outstanding
109,265,652 shares
Disclosed Ownership
2,513,110 shares
Ownership
2.3%
Form type
SCHEDULE 13G/A
Filing time
13 Feb 2026, 16:10:03 UTC
Date of event
31 Dec 2025
Previous filing
14 Aug 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"MAVERICK CAPITAL LTD disclosed 2.3% ownership in Rocket Pharmaceuticals, Inc. Common stock, $0.01 par value per share (RCKT) on 31 Dec 2025."

Quick Takeaways

  • MAVERICK CAPITAL LTD filed SCHEDULE 13G/A for Rocket Pharmaceuticals, Inc. Common stock, $0.01 par value per share (RCKT).
  • Disclosed ownership: 2.3%.
  • Date of event: 31 Dec 2025.

What Changed

  • Previous schedule filing date: 14 Aug 2025.
  • Current filing was accepted on 13 Feb 2026, 16:10.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (3)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Maverick Capital, Ltd. 2.3% 2,513,110 0 2,513,110 /s/ Trevor Wiessmann* By: Maverick Capital Management, LLC, its General Partner By: Lee S. Ainslie III, Manager
Maverick Capital Management, LLC 2.3% 2,513,110 0 2,513,110 /s/ Trevor Wiessmann* Lee S. Ainslie III, Manager
Lee S. Ainslie III 2.3% 2,513,110 0 2,513,110 /s/ Trevor Wiessmann* Lee S. Ainslie III

Sponsored